DE60238486D1 - Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen - Google Patents

Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen

Info

Publication number
DE60238486D1
DE60238486D1 DE60238486T DE60238486T DE60238486D1 DE 60238486 D1 DE60238486 D1 DE 60238486D1 DE 60238486 T DE60238486 T DE 60238486T DE 60238486 T DE60238486 T DE 60238486T DE 60238486 D1 DE60238486 D1 DE 60238486D1
Authority
DE
Germany
Prior art keywords
cells
hematopoetic
genetic modification
temporary
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238486T
Other languages
English (en)
Inventor
Geoffery P Symonds
Rafael Amado
Lun-Quan Sun
Janet Macpherson
Greg Fanning
Wayne Gerlach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Research Pty Ltd
Original Assignee
Johnson and Johnson Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Research Pty Ltd filed Critical Johnson and Johnson Research Pty Ltd
Application granted granted Critical
Publication of DE60238486D1 publication Critical patent/DE60238486D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
DE60238486T 2001-07-10 2002-07-10 Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen Expired - Lifetime DE60238486D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30428301P 2001-07-10 2001-07-10
US30412701P 2001-07-10 2001-07-10
US34348401P 2001-12-21 2001-12-21
US38606302P 2002-06-04 2002-06-04
PCT/US2002/021907 WO2003006691A1 (en) 2001-07-10 2002-07-10 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells

Publications (1)

Publication Number Publication Date
DE60238486D1 true DE60238486D1 (de) 2011-01-13

Family

ID=27501852

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238486T Expired - Lifetime DE60238486D1 (de) 2001-07-10 2002-07-10 Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen

Country Status (16)

Country Link
US (2) US7345025B2 (de)
EP (2) EP1414996B1 (de)
JP (2) JP5179697B2 (de)
KR (1) KR101015913B1 (de)
CN (2) CN1553963A (de)
AT (1) ATE490322T1 (de)
AU (1) AU2002316640C1 (de)
BR (1) BR0211079A (de)
CA (1) CA2453531A1 (de)
DE (1) DE60238486D1 (de)
DK (1) DK1414996T3 (de)
HK (1) HK1065074A1 (de)
IL (2) IL159637A0 (de)
MX (1) MXPA04000268A (de)
NZ (1) NZ530624A (de)
WO (1) WO2003006691A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
CA2279673A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acids for therapeutic and diagnostic uses
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
IL159637A0 (en) 2001-07-10 2004-06-01 Johnson & Johnson Res Pty Ltd Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
IL159777A0 (en) * 2001-07-10 2004-06-20 J & J Res Pty Ltd Production of transduced hematopoietic progenitor cells
ES2358187T3 (es) 2001-07-10 2011-05-06 JOHNSON & JOHNSON RESEARCH PTY LIMITED Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas.
US7737124B2 (en) * 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
AU2002326906C1 (en) * 2001-09-13 2009-01-29 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
DE10212892A1 (de) * 2002-03-20 2003-10-09 Basf Plant Science Gmbh Konstrukte und Verfahren zur Regulation der Genexpression
DE10224750A1 (de) 2002-06-04 2003-12-24 Fresenius Medical Care De Gmbh Vorrichtung zur Behandlung einer medizinischen Flüssigkeit
US20040197316A1 (en) * 2003-02-06 2004-10-07 Tsokos George C. Novel method for the treatment of systemic lupus erythematosus
CA2519975C (en) * 2003-04-08 2013-07-02 Yeda Research And Development Co. Ltd Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
GB0410130D0 (en) * 2004-05-06 2004-06-09 Molmed Spa Cell preparation
US7935074B2 (en) * 2005-02-28 2011-05-03 Fresenius Medical Care Holdings, Inc. Cassette system for peritoneal dialysis machine
US8197231B2 (en) 2005-07-13 2012-06-12 Purity Solutions Llc Diaphragm pump and related methods
WO2007011088A1 (en) * 2005-07-20 2007-01-25 Seoul National University Industry Foundation Method for culturingand proliferating hematopoietic stem cells and progenitor cells using human endometrial cells
EP2489728A1 (de) * 2006-06-15 2012-08-22 Neostem, Inc Verarbeitungsverfahren für periphere Blutstammzellen
JP2011160661A (ja) * 2008-06-02 2011-08-25 Kyowa Hakko Kirin Co Ltd 血球細胞の初期化法
US8112365B2 (en) * 2008-12-19 2012-02-07 Foster Scott C System and method for online employment recruiting and evaluation
US20100210989A1 (en) 2008-12-23 2010-08-19 Janet Lesley Macpherson Processing blood
US8192401B2 (en) 2009-03-20 2012-06-05 Fresenius Medical Care Holdings, Inc. Medical fluid pump systems and related components and methods
US20120034197A1 (en) * 2009-04-09 2012-02-09 Stemcyte Inc. Hiv-resistant stem cells and uses thereof
WO2011008858A1 (en) 2009-07-15 2011-01-20 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US8720913B2 (en) 2009-08-11 2014-05-13 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis carts and related systems
EP2647697B1 (de) * 2010-12-01 2016-08-24 Nissan Chemical Industries, Ltd. Verfahren zur herstellung hämatopoietischer stammzellen mithilfe einer pyrazolverbindung
DE102010053973A1 (de) 2010-12-09 2012-06-14 Fresenius Medical Care Deutschland Gmbh Medizinisches Gerät mit einer Heizung
WO2012087798A2 (en) 2010-12-20 2012-06-28 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9624915B2 (en) 2011-03-09 2017-04-18 Fresenius Medical Care Holdings, Inc. Medical fluid delivery sets and related systems and methods
MX341315B (es) 2011-04-21 2016-08-12 Fresenius Medical Care Holdings Inc Sistemas de bombeo de fluido medico y dispositivos y metodos relacionados.
US9186449B2 (en) 2011-11-01 2015-11-17 Fresenius Medical Care Holdings, Inc. Dialysis machine support assemblies and related systems and methods
US9610392B2 (en) 2012-06-08 2017-04-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9500188B2 (en) 2012-06-11 2016-11-22 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
PT2892330T (pt) * 2012-09-07 2023-02-17 Institute For Res In Biomedicine Irb Ratinhos geneticamente modificados e métodos de utilização dos mesmos
AU2013337242B2 (en) * 2012-11-05 2019-04-04 Institute For Research In Biomedicine (Irb) Genetically modified non-human animals and methods of use thereof
US10077426B2 (en) 2012-12-06 2018-09-18 Enlivex Therapeutics Ltd Therapeutic apoptotic cell preparations, method for producing same and uses thereof
US9561323B2 (en) 2013-03-14 2017-02-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassette leak detection methods and devices
US10117985B2 (en) 2013-08-21 2018-11-06 Fresenius Medical Care Holdings, Inc. Determining a volume of medical fluid pumped into or out of a medical fluid cassette
CN103471896A (zh) * 2013-09-09 2013-12-25 上海兰卫临床检验有限公司 革兰染色液质控品制备方法
EP3615044A4 (de) * 2017-04-27 2021-01-20 Fred Hutchinson Cancer Research Center Therapeutische formulierungen mit cd34+-stammzellen aus negativer selektion
JP2021503015A (ja) * 2017-11-15 2021-02-04 ウィヤード・サイエンス・エルエルシー 非骨髄破壊的な骨髄再構成のための方法および組成物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3046318B2 (ja) 1987-12-15 2000-05-29 ジーン・シアーズ・ピーティーワイ・リミテッド リボザイム
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
US5866701A (en) 1988-09-20 1999-02-02 The Board Of Regents For Northern Illinois University Of Dekalb HIV targeted hairpin ribozymes
US4978514A (en) 1989-09-12 1990-12-18 Fuel Tech, Inc. Combined catalytic/non-catalytic process for nitrogen oxides reduction
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5500357A (en) 1990-11-02 1996-03-19 Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry RNA transcription system using novel ribozyme
CA2107789A1 (en) 1991-04-05 1992-10-06 Thomas E. Wagner Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences
US5525468A (en) 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
US5693535A (en) 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
CA2137161C (en) 1992-06-29 2007-09-18 David G. Atkins Nucleic acids and methods of use thereof for controlling viral pathogens
JPH08505872A (ja) 1993-01-22 1996-06-25 ユニバーシティ・リサーチ・コーポレイション 治療剤の局所化
IL108719A0 (en) 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
WO1995004818A1 (en) 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
WO1995018854A1 (en) 1994-01-05 1995-07-13 Gene Shears Pty., Ltd. Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US5712384A (en) 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US20020058636A1 (en) 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
CA2216868A1 (en) 1995-04-20 1996-10-24 Chiron Corporation High efficiency ex vivo transduction of hematopoietic stem cells by recombinant retroviral preparations
US5741706A (en) 1996-06-13 1998-04-21 Immusol, Incorporated Anti-HIV ribozymes
TWI239352B (en) 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6060317A (en) * 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto
AU2036700A (en) 1998-12-04 2000-06-26 City Of Hope A method of genetically modifying very primitive quiescent human hematopoietic stem cells
AU5403100A (en) * 1999-06-08 2000-12-28 Novartis Ag Enforced expression of bcl-xl
AU2001290795A1 (en) 2000-09-13 2002-03-26 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖ｒｎａ仲介遺伝子抑制
IL159637A0 (en) 2001-07-10 2004-06-01 Johnson & Johnson Res Pty Ltd Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
ES2358187T3 (es) 2001-07-10 2011-05-06 JOHNSON & JOHNSON RESEARCH PTY LIMITED Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas.
IL159777A0 (en) 2001-07-10 2004-06-20 J & J Res Pty Ltd Production of transduced hematopoietic progenitor cells
KR100646702B1 (ko) * 2001-08-16 2006-11-17 에스케이씨 주식회사 홀 및/또는 그루브로 형성된 화학적 기계적 연마패드

Also Published As

Publication number Publication date
US20040072771A1 (en) 2004-04-15
JP2005528319A (ja) 2005-09-22
EP1414996B1 (de) 2010-12-01
NZ530624A (en) 2009-02-28
KR101015913B1 (ko) 2011-02-23
JP2010077125A (ja) 2010-04-08
JP5179697B2 (ja) 2013-04-10
MXPA04000268A (es) 2005-03-07
DK1414996T3 (da) 2011-03-21
EP2322618A1 (de) 2011-05-18
HK1065074A1 (en) 2005-02-08
ATE490322T1 (de) 2010-12-15
IL159637A0 (en) 2004-06-01
EP1414996A1 (de) 2004-05-06
US7776595B2 (en) 2010-08-17
CN1553963A (zh) 2004-12-08
EP1414996A4 (de) 2007-03-28
KR20040032852A (ko) 2004-04-17
US7345025B2 (en) 2008-03-18
US20080044394A1 (en) 2008-02-21
AU2002316640C1 (en) 2009-01-29
AU2002316640B2 (en) 2008-06-12
IL159637A (en) 2013-07-31
BR0211079A (pt) 2005-08-30
CA2453531A1 (en) 2003-01-23
WO2003006691A1 (en) 2003-01-23
CN101926824A (zh) 2010-12-29

Similar Documents

Publication Publication Date Title
DE60238486D1 (de) Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen
DE602005012276D1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
DE602005019064D1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EP1196444B8 (de) Exendin-4 konjugate und ihre medizinische verwendung
SI1615952T1 (sl) Metoda zdravljenja vnetnih bolezni z uporabo specifičnih veznih sredstev humanega angiopoetin
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
BR0315689A (pt) Alvo para terapia de dano cognitivo
DE60233805D1 (de) Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen
WO2002064096A3 (en) Methods of using pyrimidine-based antiviral agents
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
EP1362127A4 (de) Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung
DK2229440T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
DE60335647D1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
ATE527377T1 (de) Erstellung von genexpressionprofilen aus ffpe- proben
DK1793859T3 (da) Behandling af oral og intestinal mucositis ved indgivelse af humant IL-18
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
ATE431399T1 (de) Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
DE60140950D1 (de) Neuer gentherapeutischer wirkstoff zur behandlung g
ATE398188T1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
ATE498397T1 (de) Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion